Hims and other telehealth companies make finasteride easy to get and don’t have to disclose side effects in ads.

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Telehealth stock Hims & Hers (HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy. The ad criticized the American ...

The minute-long ad from telehealth company Hims & Hers shows imagery including a scale, food including pies and cheeseburgers, and a refrigerator full of vials of Hims & Hers-labeled medications ...

Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing hair-loss ...

Hims & Hers Health has undeniably captured market attention and investor enthusiasm, fueled by a successful Super Bowl ad campaign and its strategic entry into the high-demand GLP-1 weight loss ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site. The ad also hit a nerve with the pharma industry, lawmakers and some industry groups. The ad ...

Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...

In its recent Super Bowl ad, the telehealth provider Hims & Hers went on the attack against something bigger: “the system.” Promoting a weight-loss drug positioned as a cheaper Ozempic ...

Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (NYSE: HIMS) ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.